Personalized therapy of sarcomas: Integration of biomarkers for improved diagnosis, prognosis, and therapy selection

Current Oncology Reports

Volumn 10, Issue 4, 2008, Pages 329-337

  Ludwig, Joseph A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BEVACIZUMAB; BRCA1 PROTEIN; CD99 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FAS ANTIGEN; GEMCITABINE; GLUCOSE TRANSPORTER 1; IFOSFAMIDE; IMATINIB; KI 67 ANTIGEN; MESSENGER RNA; MYC PROTEIN; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53; RITUXIMAB; SOMATOMEDIN C; STAT3 PROTEIN; STEM CELL FACTOR; SURVIVIN; TRABECTEDIN; TRASTUZUMAB; UNINDEXED DRUG; WT1 PROTEIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN; TUMOR MARKER;

ALVEOLAR SOFT PART SARCOMA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER GROWTH; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHONDROSARCOMA; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLEAR CELL SARCOMA; DERMATOFIBROSARCOMA PROTUBERANS; DESMOPLASTIC SMALL ROUND CELL TUMOR; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG EFFICACY; DRUG RESPONSE; EWING SARCOMA; FIBROSARCOMA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENETIC RISK; HEMANGIOENDOTHELIOMA; HISTOPATHOLOGY; HUMAN; LYMPHOMA; MALIGNANT FIBROUS HISTIOCYTOMA; MYXOSARCOMA; OSTEOSARCOMA; PREDICTION; PREVALENCE; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RHABDOMYOSARCOMA; RISK FACTOR; SARCOMA; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; CHEMISTRY; SOFT TISSUE TUMOR;

HUMANS; PROGNOSIS; SARCOMA; SOFT TISSUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 56149118853     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-008-0051-6     Document Type: Review

References (50)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66.
2. Schöffski P, Wolter P, Clement P, et al.: Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma. Future Oncol 2007, 3:381-392.
3. Spira AI, Ettinger DS: The use of chemotherapy in soft-tissue sarcomas. Oncologist 2002, 7:348-359.
4. ESobin LH: TNM: evolution and relation to other prognostic factors. Semin Surg Oncol 2003, 21:3-7.
5. Broders AC, Hargrave R, Meyerding HW: Pathological features of soft tissue sarcoma; with special reference to the grading of its malignancy. Surg Gynecol Obstet 1939, 69:267-280.
6. Hoos A, Stojadinovic A, Mastorides S, et al.: High Ki-67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas. Cancer 2001, 92:869-874.
7. Kattan MW, Leung DH, Brennan MF: Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol 2002, 20:791-796.
8. Eilber FC, Brennan MF, Eilber FR, et al.: Validation of the postoperative nomogram for 12-year sarcoma-specific mortality. Cancer 2004, 101:2270-2275.
9. Mariani L, Miceli R, Kattan MW, et al.: Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. Cancer 2005, 103:402-408.
10. Ravdin PM, Siminoff LA, Davis GJ, et al.: Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001, 19:980-991.
11. de Alava E, Kawai A, Healey JH, et al.: EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 1998, 16:1248-1255.
12. Lin PP, Brody RI, Hamelin AC, et al.: Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma. Cancer Res 1999, 59:1428-1432.
13. Zoubek A, Dockhorn-Dworniczak B, Delattre O, et al.: Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol 1996, 14:1245-1251.
14. Maki RG, Wathen JK, Patel SR, et al.: Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: Results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 2007, 25:2755-2763.
15. Druker BJ, Sawyers CL, Kantarjian H, et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344:1038-1042.
16. Balmain A, Gray J, Ponder B: The genetics and genomics of cancer. Nat Genet 2003, 33(Suppl):238-244.
17. Steinert DM, Oyarzo M, Wang X, et al.: Expression of Bcl-2 in gastrointestinal stromal tumors: Correlation with progression-free survival in 81 patients treated with imatinib mesylate. Cancer 2006, 106:1617-1623.
18. Osaka E, Suzuki T, Osaka S, et al.: Survivin expression levels as independent predictors of survival for osteosarcoma patients. J Orthop Res 2007, 25:116-121.
19. Taubert H, Würl P, Greither T, et al.: Stem cell-associated genes are extremely poor prognostic factors for soft-tissue sarcoma patients. Oncogene 2007, 26:7170-7174.
20. Kim MS, Song WS, Cho WH, et al.: Ezrin expression predicts survival in stage IIB osteosarcomas. Clin Orthop Relat Res 2007, 459:229-236.
21. Bartel F, Meye A, Würl P, et al.: Amplification of the MDM2 gene, but not expression of splice variants of MDM2 MRNA, is associated with prognosis in soft tissue sarcoma. Int J Cancer 2001, 95:168-175.
22. Taubert H, Koehler T, Meye A, et al.: Mdm2 mRNA level is a prognostic factor in soft tissue sarcoma. Mol Med 2000, 6:50-59.
23. Bodner K, Bodner-Adler B, Kimberger O, et al.: Bcl-2 expression and other clinicopathologic parameters in uterine leiomyosarcoma. Wien Klin Wochenschr 2004, 116:135-139.
24. Honoki K, Stojanovski E, McEvoy M, et al.: Prognostic significance of p16 INK4a alteration for Ewing sarcoma: A meta-analysis. Cancer 2007, 110:1351-1360.
25. Endo M, Tateishi U, Seki K, et al.: Prognostic implications of glucose transporter protein-1 (glut-1) overexpression in bone and soft-tissue sarcomas. Jpn J Clin Oncol 2007, 37:955-960.
26. Sato O, Wada T, Kawai A, et al.: Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: A clinicopathologic study of 281 cases. Cancer 2005, 103:1881-1890.
27. Lai R, Navid F, Rodriguez-Galindo C, et al.: STAT3 is activated in a subset of the Ewing sarcoma family of tumours. J Pathol 2006, 208:624-632.
28. Koshkina NV, Khanna C, Mendoza A, et al.: Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: The role of the Fas pathway in the metastatic process of osteosarcoma. Mol Cancer Res 2007, 5:991-999.
29. Morrison C, Radmacher M, Mohammed N, et al.: MYC amplification and polysomy 8 in chondrosarcoma: Array comparative genomic hybridization, fluorescent in situ hybridization, and association with outcome. J Clin Oncol 2005, 23:9369-9376.
30. Scotlandi KA Baldini N, Cerisano N, et al.: CD99 engagement: an effective therapeutic strategy for Ewing tumors. Cancer Res 2000, 60:5134-5142.
31. Beech DJ, Perer E, Helms J, et al.: Insulin-like growth factor-I receptor activation blocks doxorubicin cytotoxicity in sarcoma cells. Oncol Rep 2003, 10:181-184.
32. Ma Z, Dong A, Kong M, Qian J: Silencing of the type 1 insulin-like growth factor receptor increases the sensitivity to apoptosis and inhibits invasion in human lung adenocarcinoma A549 cells. Cell Mol Biol Lett 2007, 12:556-572.
33. Meyers PA, Heller G, Healey J, et al.: Chemotherapy for nonmetastatic osteogenic sarcoma: The Memorial Sloan-Kettering experience. J Clin Oncol 1992, 10:5-15.
34. Meyers PA, Heller G, Healey JH, et al.: Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol 1993, 11:449-453.
35. Bielack SS, Kempf-Bielack B, Delling G, et al.: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002, 20:776-790.
36. Sato J, Yanagawa T, Dobashi Y, et al.: Prognostic significance of 18F-FDG uptake in primary osteosarcoma after but not before chemotherapy: A possible association with autocrine motility factor/ phosphoglucose isomerase expression. Clin Exp Metastasis 2008 (ePub ahead of print).
37. Hawkins DS, Schuetze SM, Butrynski JE, et al.: [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 2005, 23:8828-8834.
38. Brisse H, Ollivier L, Edeline V, et al.: Imaging of malignant tumours of the long bones in children: Monitoring response to neoadjuvant chemotherapy and preoperative assessment. Pediatr Radiol 2004, 34:595-605.
39. Goldstein D, Tan BS, Rossleigh M, et al.: Gastrointestinal stromal tumours: Correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response - an AGITG study. Oncology 2005, 69:326-332.
40. Benjamin RS, Choi H, Macapinlac HA, et al.: We should desist using RECIST, at least in GIST. J Clin Oncol 2007, 25:1760-1764.
41. Burke M, Anderson JR, Kao SC, et al.: Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: The Intergroup Rhabdomyosarcoma Study-IV experience - a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol 2007, 25:4909-4913.
42. West DC, Grier HE, Swallow MM, et al.: Detection of circulating tumor cells in patients with Ewing's sarcoma and peripheral primitive neuroectodermal tumor. J Clin Oncol 1997, 15:583-588.
43. Hammond ME, Taube SE: Issues and barriers to development of clinically useful tumor markers: A development pathway proposal. Semin Oncol 2002, 29:213-221.
44. Pepe MS, Etzioni R, Feng Z, et al.: Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001, 93:1054-1061.
45. Barker PE: CancerRbiomaSker validation: standards and process: roles for the National Institute of Standards and Technology (NIST). Ann N Y Acad Sci 2003, 983:142-150.
46. Ludwig JA, Weinstein JN: Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005, 5:845-856.
47. Cardoso F, Van't Veer L, Rutgers E, et al.: Clinical application of the 70-gene profile: The MINDACT trial. J Clin Oncol 2008, 26:729-735.
48. Gutman S: Regulatory issues in tumor marker development. Semin Oncol 2002, 29:294-300.
49. Taube SE, Freiberg GP: Regulatory issues related to marker development. Urol Oncol 2000, 5:214-216.
50. Hackett JL,TLesko LJ: Microarray data: the US FDA, industry and academia. Nat Biotechnol 2003, 21:742-743.